Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its phase 1/2 study of its sacituzumab tirumotecan drug during a meeting of the American Society of Clinical Oncology in San Francisco from Thursday to Saturday.
The drug is indicated for patients with locally advanced or metastatic urothelial carcinoma who have shown progress on or after prior anti-cancer treatments, according to a Tuesday filing with the Hong Kong exchange.
The drug has previous indications for advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors, among others, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。